Exosomes and extracellular vesicles — the cell-to-cell communication system you didn't learn about

That assumption held for about twenty years.

What those researchers had glimpsed was the edge of a biology that turns out to be fundamental. The bubbles — extracellular vesicles — are not garbage. They're messages. Every cell in your body produces them continuously, and other cells pick them up, read their contents, and change their behavior accordingly. This is cell-to-cell communication at a scale and sophistication that sits entirely outside the classical picture of hormones binding receptors and signaling cascades running downstream. It's a parallel messaging system that biology had been running the entire time, and we had no idea.

Understanding it from the ground up requires starting with the biology.

Extracellular vesicles is the umbrella term, and there are three main populations worth distinguishing. Exosomes are the smallest — thirty to one hundred fifty nanometers in diameter — and they originate in a specific way: inside endosomes, the cell's internal sorting compartments, small vesicles bud inward from the endosomal membrane and accumulate there. When the endosome containing them fuses with the cell's outer membrane, it expels them into the extracellular space. They're sometimes called exosomes because of this roundabout route — they exit the cell via that endosomal pathway rather than budding directly from the cell surface. Microvesicles, the middle category, are larger — roughly one hundred to one thousand nanometers — and they bud directly from the plasma membrane, pinching off outward. Apoptotic bodies are the largest, released by cells in the process of dying, and they contain a more chaotic cargo including fragments of nuclear DNA. All three types travel through extracellular fluid, enter the bloodstream and lymphatic system, and reach cells throughout the body.

What they carry is the key to why they matter. The cargo inside a vesicle is not random. The cell selects it — imperfectly, but selectively. A vesicle can contain proteins, lipids, messenger RNAs, microRNAs, and fragments of DNA. MicroRNAs are especially important here: they're short regulatory RNA sequences that, when delivered to a target cell, can bind to messenger RNAs and suppress their translation into protein, effectively silencing genes in the recipient cell. When a muscle cell releases vesicles carrying microRNAs into circulation during exercise, those vesicles may reach liver cells, fat cells, immune cells, and neurons, delivering molecular instructions from a tissue that just worked hard to tissues that didn't. The recipient cell has no way to originate a signal like this on its own. It's receiving a message from somewhere else in the body, and the message is specific.

The mechanism of delivery depends on the vesicle and the target cell. Some vesicles fuse directly with the target cell membrane, depositing their contents into the cytoplasm. Others are taken up by endocytosis — the cell engulfs the vesicle and traffics it internally. In either case, the cargo reaches the cell interior. This is meaningfully different from a hormone binding a surface receptor: with receptor binding, the signal is transduced through a cascade that the cell mediates. With vesicle delivery, foreign RNA and protein arrive directly inside the target cell, ready to act.

The research that changed how the field thought about this happened in the early 2000s, in a series of publications by researchers including Jan Lötvall, Graça Raposo, and colleagues studying immune cell biology. What they showed, most compellingly in a 2007 paper, was that exosomes could transfer functional mRNA between cells — and that the transferred mRNA could be translated into protein in the recipient cell. This was a different kind of communication than anyone had been thinking about. Not chemical signaling at the cell surface, but genomic instruction delivered across cellular boundaries. The implications were large enough that the field's energy shifted dramatically, and the term "exosome" moved from a footnote in cell biology textbooks to one of the most-searched terms in the biomedical literature.

The aging connection runs in several directions.

The first is what happens to vesicle composition as the body ages. Older cells produce vesicles with different cargo than younger cells — different microRNA profiles, different protein loads, altered lipid composition. This matters because vesicles from aged cells may instruct recipient cells to behave like aged cells. Research in animal models has demonstrated that young blood has rejuvenating effects on old tissues — this is the parabiosis line of evidence, where surgically connecting the circulatory systems of young and old mice produced improvements in muscle regeneration, cognitive function, and other aging markers in the older animal. For a long time the assumption was that this was driven by soluble proteins circulating in young plasma. The extracellular vesicle research added a new candidate: young vesicles, with their distinct cargo, might be doing significant work in that parabiosis signal.

Senescent cells — cells that have stopped dividing but haven't died — make this picture considerably more complicated. Senescent cells are producers of a characteristic secretory profile called the SAPS, or senescence-associated secretory phenotype. That profile includes cytokines, proteases, and growth factors that drive chronic inflammation and degrade tissue function around the senescent cell. It turns out that senescent cells also release a characteristic population of extracellular vesicles, and those vesicles carry pro-inflammatory and pro-senescent cargo. Animal studies have shown that vesicles from senescent cells can induce senescence in healthy recipient cells — a spreading of cellular dysfunction via vesicular message. When senescent cells accumulate with age (as they do), their vesicle output may be part of the mechanism by which focal senescence becomes systemic inflammation.

The therapeutic interest took off in two directions simultaneously. The first was stem cell-derived exosomes as a cell-free regenerative therapy. Mesenchymal stem cells, or MSCs, had been studied for decades as a potential regenerative treatment — the idea being that injecting them into damaged tissue would support repair. The clinical results were mixed. Researchers began to ask whether the benefits weren't coming from the cells themselves but from the vesicles they secreted. MSC-derived exosomes, in animal models and some early clinical studies, showed effects on wound healing, inflammatory modulation, and tissue repair that appeared to recapitulate much of what the parent cells did. The appeal was practical: exosomes are smaller than cells, potentially more stable, don't carry the same risks of immune rejection, and can be produced, filtered, and standardized in ways that cells cannot. A large industry has built up around this premise.

The second direction was drug delivery. Exosomes are, in some ways, a nearly ideal drug delivery vehicle: they're naturally occurring particles that the body is already fluent in processing, they're small enough to cross the blood-brain barrier in some contexts, and they can be engineered to carry specific cargo and to display surface proteins that direct them toward specific cell types. Researchers have loaded exosomes with small interfering RNAs, chemotherapy agents, and CRISPR components and demonstrated targeted delivery in animal models. Whether this translates into clinically viable therapeutics is still being worked out, but the early work is compelling enough that pharmaceutical companies have built entire programs around it.

The third direction is diagnostics. Circulating extracellular vesicles in blood, urine, and cerebrospinal fluid carry cargo that reflects the state of the tissues that produced them. Tumor cells shed vesicles with characteristic molecular signatures — which has led to research on liquid biopsy approaches that could detect cancer from a blood draw. Vesicle cargo from brain tissue appears in cerebrospinal fluid and potentially in peripheral blood in ways that could serve as biomarkers for Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. The diagnostic promise is real and ahead of the therapeutic promise, in part because biomarker validation is a faster path than therapeutic validation.

The FDA's position on the consumer exosome market deserves its own clear statement. The agency has issued multiple warning letters to companies marketing exosome products for injection — as skin rejuvenation therapies, anti-aging infusions, post-procedure recovery treatments — that are not approved biologics. The FDA has stated explicitly that these products are not approved, that the manufacturing and characterization standards of many commercial exosome preparations are not established, and that injecting unapproved biological preparations carries risks that cannot be dismissed. The science underlying extracellular vesicle biology is not in question. The specific commercial products being sold in medspa contexts, claiming to harness that science for observable rejuvenation, are in a different category: they are significantly ahead of the clinical evidence, and the regulatory status is clear. Mesenchymal stem cell-derived exosome therapeutics that will eventually be viable will come through clinical trial programs with manufacturing standards and efficacy data. The current consumer market is not that.

This framing matters because the underlying biology genuinely is exciting, and conflating that excitement with the current consumer offerings obscures the actual state of the science. Animal studies showing that young vesicles have rejuvenating effects, that senescent cell vesicles spread dysfunction, that MSC-derived exosomes support tissue repair — these findings are real and replicable and point to mechanisms that could eventually be therapeutic. Human clinical evidence is early and specific to particular applications; the broad anti-aging claims have no clinical support. These are honest distinctions, and they matter for anyone making decisions about what to pursue.

There's a deeper implication in the vesicle biology that goes beyond anti-aging applications.

The classical picture of how the body communicates with itself involved a relatively small cast: hormones produced by specialized glands, neurotransmitters in synaptic clefts, cytokines from immune cells, local growth factors. These signals were understood as the primary language the body used to coordinate its trillion-cell enterprise. Extracellular vesicles revealed that this picture was incomplete in a fundamental way. Every cell type produces vesicles. Muscle cells signal to the liver. Fat cells signal to the brain. Gut epithelial cells signal to distant immune compartments. The body is not a broadcast system where specialized glands speak and everyone listens — it's an n-way conversation in which every cell is both a sender and receiver of molecular messages, packaged in lipid envelopes, delivered across distances that individual molecules could never cross.

The implications of this for how we think about physiology are not yet fully mapped. When you exercise and your muscles release vesicles into circulation, what tissues receive those vesicles, and what do they do when they get there? When chronic stress drives cortisol up and degrades tissue function, is some of that effect mediated through stress-altered vesicle cargo? When a senescent cell in fat tissue releases pro-inflammatory vesicles, how far does the signal travel, and which organ systems feel it? The answers are being worked out in labs right now. The extracellular vesicle literature is currently among the fastest-growing in all of biomedical research, measured by publication count and funding.

What this means for understanding aging specifically is that the body's condition may be far more coordinated — and far more tractable — than the organ-by-organ model suggested. Aging isn't purely a local phenomenon, something that happens independently in the heart and then independently in the brain and then independently in the muscle. It may be partly a systemic communication problem: tissues sending vesicles with the wrong messages, and recipient tissues changing their behavior accordingly. If that's true, then interventions that alter the vesicle environment — or that protect recipient cells from pro-aging vesicular signals — could have effects that ripple far beyond the original target tissue.

That's a hypothesis still in the making. But it's the most interesting question the vesicle biology raises. Not whether a medspa exosome product works, but whether the systemic aging process itself is partly a messaging problem — and whether there's a communication language deep in cell biology that, once understood precisely enough, could be translated into something therapeutically real.